Mylan Chairman Coury Handed More Central Role
Former Chairman Accelerates Into New Role Amid Coronavirus Challenge
Associated with Mylan since the mid-1990s and formerly serving as CEO for more than a decade, chairman Robert Coury has been appointed to a position of greater influence with the company, as Mylan fights battles on several fronts.
You may also be interested in...
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.
Mylan has delayed a major restructuring program ahead of its planned merger with Pfizer’s Upjohn unit due to the impact of the COVID-19 pandemic, which at the same time brought tailwinds for the firm’s first-quarter results.
The European Commission has approved Mylan’s merger with Pfizer’s Upjohn unit, on condition that the generics firm make a series of divestments in markets where the two firms’ strong positions and lack of other challengers would raise competition concerns.